Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas. - Wikidata - wikimedia - TriplyDB

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

http://www.wikidata.org/entity/Q33625227

about

Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme.Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.Trends in Malignant Glioma Monoclonal Antibody Therapy.

P2860

Q33421314-67C4D627-8F24-4060-B266-55035638A548 Q49066603-9151A7A5-D8DE-4DDB-8256-DCD385ABB4C3 Q54942652-ABC45512-B308-4870-B4CD-AE4DAD546782

P2860

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

http://www.wikidata.org/entity/Q33625227

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

@ast

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

@en

type

label

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

@ast

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

@en

prefLabel

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

@ast

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

@en

P1433

Q33625227-2B34AE7B-10B8-416B-B187-27735626B210

P1476

Q33625227-024DF7C3-205B-4386-8BB9-C888D3F2D9E0

P2093

Q33625227-1E2E8476-DDE0-4F1C-9D99-5D8FB4500277

Q33625227-4AB4B14E-E0BC-426C-84D1-0F57265BCE2B

Q33625227-574100CB-65F5-483B-AB2E-7A7ECAE1097F

Q33625227-7F9D0E9C-5C99-4BB9-9518-9C1DD571D529

Q33625227-97A82AAB-AD53-4364-BF57-1CBE49B63180

Q33625227-A2F80C04-ED5E-4094-9436-22A199924BB5

Q33625227-C457BEF2-0C2B-4448-AA21-1929BA1845C7

Q33625227-EF370C43-8A58-4607-8BDD-D7AAE3588B2C

Q33625227-F841404C-ED07-40AD-8845-680E29B9F996

P2860

Q33625227-0313FB73-9764-4586-B079-9EBB9FF7B68A

Q33625227-0B6CD8D8-673F-4608-947E-DC8FE4D45A86

Q33625227-2AEEDE6D-D459-4263-9227-E4D25B8195D6

Q33625227-2ED8A496-7A2F-48F6-BFD4-9ADECBD657A3

Q33625227-32AF4459-0119-42B0-8F4B-0951917F2A8D

Q33625227-47CD5FEA-5FEB-4BC0-B651-3647E149EB44

Q33625227-540FA967-D308-4425-84BF-B95BE9DA98ED

Q33625227-5B9ED5C5-91B7-4674-83B6-20ADB059091E

Q33625227-6468E99E-0436-4C21-9007-49446A9D9A69

Q33625227-66373E7F-F242-4EBA-B32E-4D74B32709EF

P304

Q33625227-10E19E46-B8DE-4EDA-A473-069404A6740F

P31

Q33625227-38DC5D6F-17A7-42F2-8E46-FDAB9DB9D0AF

P356

Q33625227-4156B325-A60F-424F-A414-1CC96C3A42FD

P407

Q33625227-12EAF312-5971-4254-B97E-B1CB43E80457

P478

Q33625227-769E5DB8-C3A0-438C-BB95-C00B5CD0B92E

P50

Q33625227-2988E8AE-C24F-4674-A61B-4D33226D3980

Q33625227-326536CE-ECC8-4C10-A717-DA61FF9519D0

Q33625227-62F52025-07B3-4D82-BEA2-E5B28F86D8F7

Q33625227-691A3723-0C20-496A-B6CC-EE5F0250B98F

Q33625227-99A620B9-3ABC-4204-8072-F4DB8DEB52FF

Q33625227-FFCF289E-08BC-479E-BB71-71F962ED7BC3

P577

Q33625227-BC6E90C0-9C2F-48C4-AC47-A270FDF7CBC7

P5875

Q33625227-FCB74CDF-FD3D-49C9-AA7B-2E6D292E0427

P698

Q33625227-D67133C8-AB3A-47E4-96AD-4A3F05C9C218

P921

Q33625227-45680AA7-C812-495B-8068-93CC8BEB18A4

P932

Q33625227-71D1511F-4A31-4B52-80DF-2C134EED9E72

P356

P1433

BioMed Research International

P1476

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas

@en

P2093

A Fabi

http://www.w3.org/2001/XMLSchema#string

A Pompili

http://www.w3.org/2001/XMLSchema#string

C M Carapella

http://www.w3.org/2001/XMLSchema#string

F Cognetti

http://www.w3.org/2001/XMLSchema#string

G Metro

http://www.w3.org/2001/XMLSchema#string

L Marucci

http://www.w3.org/2001/XMLSchema#string

M A Carosi

http://www.w3.org/2001/XMLSchema#string

S Vari

http://www.w3.org/2001/XMLSchema#string

V Vaccaro

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.

P304

351252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/351252

http://www.w3.org/2001/XMLSchema#string

P407

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

Antonello Vidiri

Diana Giannarelli

Francesca Piludu

Veronica Villani

P577

2014-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262776177

http://www.w3.org/2001/XMLSchema#string

P698

24877084

http://www.w3.org/2001/XMLSchema#string

P921

P932

4024398

http://www.w3.org/2001/XMLSchema#string